tirzepatide vs mazdutide
updated
tirzepatide (tier S) vs mazdutide (tier A): what each is, half-life and source counts side by side.
tirzepatide · tier S
A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.
tier rationale
Tirzepatide is in S tier because large randomized trials have shown weight loss, improved blood-sugar control and reduced sleep-apnea severity. Zepbound and Mounjaro have US approvals for these uses.
mazdutide · tier A
the GLP-1 + glucagon dual agonist approved in China. ~14% weight loss in GLORY-1 phase 3 at 48 weeks, ~20% at the higher dose. not FDA-approved.
tier rationale
mazdutide clears a high bar: a pivotal phase 3 obesity readout (GLORY-1, ~14% at 6 mg over 48 weeks; ~20% at 9 mg in the GLORY-2 program) and a 2025 NMPA approval in China for chronic weight management and type 2 diabetes. that is real efficacy with a real label behind it. it lands at A rather than S because the pivotal efficacy was generated in a single-ethnicity Chinese population and there is no US approval, only an active US phase 2 program. strong dual-agonist data, narrower geographic and regulatory reach than the FDA-approved incretins.
at a glance
| tirzepatide | mazdutide | |
|---|---|---|
| tier | S | A |
| category | weight loss | weight loss |
| sources | 20 | 5 |
| claims evaluated | n/a | 7 |
| half-life | ~5 days | ~once-weekly dosing |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.